Novo Nordisk Inc.
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit www.novonordisk.com.
DAA Priorities for 2015
The Diabetes Advocacy Alliance (DAA) has public policy and legislative priorities in three areas: Prevention of type 2 diabetes; improved screening and detection of those adults with prediabetes and undiagnosed diabetes; and improved care for people whose diabetes has been diagnosed. A summary of DAA and DAA member priorities in diabetes is presented in this document: Advocacy Priorities in 2015.